Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry
- 22 October 2025
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Abstract
Objective: The objective of this study was to assess the risk of cancer in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs). Methods: We analysed the 2000–2023 data for RA patients from the BIOBADASER III registry, a multicentre national registry of patients treated with b/tsDMARDs. Patients with a history of cancer were excluded. Incidence rates (IRs) were analysed, and adjusted Cox regression models were used to estimate hazard ratios (HRs) for all cancers excluding non-melanoma skin cancer (NMSC), as well as for NMSC. Treatment with a TNF inhibitor (TNFi) served as the reference for comparison. Results: Among 4635 of the BIOBADASER III registry patients with RA (mean age 55.5 years; 79% female; median follow-up 3.6 years), 187 incident cancers were identified. For all cancers excluding NMSC, the adjusted HRs (95% CI) compared with TNFi were: 1.2 (0.8–1.6) for IL6i, 0.9 (0.5–1.4) for CD20i, 1.2 (0.8–1.8) for JAKi and 1.1 (0.8–1.6) for CTLA4-A. For NMSC, the adjusted HRs (95% CI) were 0.6 (0.2–1.5) for IL6i, 0.6 (0.2–1.8) for CD20i, 0.7 (0.2–2) for JAKi, and 1.1 (0.5–2.6) for CTLA4-A. No increased cancer risk was observed when adjusting for cardiovascular risk or treatment line, for either cancer type. Conclusion: In this large, real-world cohort of RA patients, we found no increased cancer risk associated with any bDMARDs or tsDMARDs compared with TNFi.Keywords
Funding Information
- Spanish Drug Agency (AEMPS), AbbVie, Bristol-Myers Squibb, Celltrion, Eli Lilly, Galápagos, Janssen, MSD, Novartis, Pfizer, Sanofi, Samsung Bioepis, and UCB
This publication has 31 references indexed in Scilit:
- Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR‐RA) StudyArthritis & Rheumatology, 2022
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis Care & Research, 2021
- Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis RegistryACR Open Rheumatology, 2021
- Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-AnalysisMayo Clinic Proceedings, 2020
- Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial DataRheumatology and Therapy, 2019
- Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin InhibitorsJAMA Network Open, 2019
- Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical PracticeJAMA Internal Medicine, 2017
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis & Rheumatism, 2006
- The Risk of Lymphoma Development in Autoimmune DiseasesArchives of internal medicine (1960), 2005